Updated
Updated November 1, 2026
Abstract
Testosterone replacement therapy (TRT) is available in the United States in multiple FDA-approved formulations, including intramuscular and subcutaneous injections, transdermal gels and solutions, oral testosterone undecanoate capsules, intranasal gels, and subcutaneous implants. Previously approved formulations include transdermal patches and buccal systems. These preparations differ in pharmacokinetics, administration frequency, dose flexibility, serum testosterone fluctuations, safety profiles, cost, and patient convenience [1,2].
This review provides a comprehensive comparison of FDA-approved testosterone formulations, including branded and generic preparations, pharmaceutical companies, regulatory approval information, dosing characteristics, advantages, disadvantages, and clinical considerations. Historical and discontinued products are distinguished from contemporary formulations.
Comparative evidence suggests formulation-related differences in hematocrit elevation, although direct head-to-head evidence remains limited. Cardiovascular outcomes data from the TRAVERSE trial support the cardiovascular noninferiority of the testosterone gel regimen studied but cannot automatically be extrapolated to all testosterone preparations [3,4].
Regulatory scope: FDA-approved testosterone products in the United States, including historical formulations. Methyltestosterone is discussed separately because it is a synthetic androgen rather than testosterone itself.
1. Introduction
Testosterone therapy is prescribed for men with hypogonadism associated with specified medical conditions. Multiple FDA-approved formulations permit individualized treatment according to patient preferences, clinical characteristics, adherence, pharmacokinetic requirements, and tolerability [1,2].
In February 2025, the FDA announced class-wide testosterone labeling changes following evaluation of TRAVERSE and ambulatory blood pressure monitoring studies. These included removal of boxed-warning language concerning increased cardiovascular outcomes and additional blood pressure warnings [5].
In June 2026, the FDA requested further labeling revisions concerning age-related hypogonadism and prostate-related safety information [6].
Despite the availability of numerous preparations for men, no systemic testosterone product is FDA-approved specifically for treating hypoactive sexual desire disorder (HSDD) or other symptoms in women [7].
2. Regulatory definitions and terminology
An FDA-approved testosterone product may be marketed under a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA). FDA approval does not necessarily mean a product remains commercially available.
FDA-approved: A product for which the FDA has approved an NDA or ANDA.
Currently marketed: A product actively distributed commercially.
Discontinued: A product no longer marketed. Discontinuation does not necessarily mean withdrawal for safety or efficacy reasons.
NDA: A New Drug Application, generally used for approval of a new branded drug product.
ANDA: An Abbreviated New Drug Application, generally used for approval of a generic drug product that meets applicable requirements for pharmaceutical equivalence and bioequivalence.
The pharmaceutical companies listed in this article include associated FDA applicants, marketers, or historical manufacturers. Where ownership has changed, both contemporary and former companies may be identified. These names are not necessarily identical to the current FDA application holder.
Approval years refer to the relevant product or formulation rather than the original approval of testosterone as an active ingredient. FDA Drugs@FDA and the Orange Book provide authoritative application-level records [8,9].
Understanding the Terminology: Formulations vs. Preparations
Although the terms formulation and preparation are frequently used interchangeably in clinical literature, they have slightly different meanings in pharmaceutical science.
Testosterone formulation refers to the specific composition and dosage form of a testosterone-containing drug, including the active ingredient, concentration, excipients, and delivery system. These characteristics influence absorption, pharmacokinetics, stability, and administration.
Examples: Testosterone gel 1.62%, testosterone cypionate 200 mg/mL injectable solution, and oral testosterone undecanoate capsules.
Testosterone preparation is a broader term describing a testosterone-containing medicinal product prepared for clinical administration. It may refer to a particular formulation, a branded or generic product, or a category of products delivered through a specific route.
Examples: AndroGel 1.62% (AbbVie), Depo-Testosterone (Pfizer), and Jatenzo (Tolmar Pharmaceuticals).
Key distinction
A formulation emphasizes what a drug contains and how it is designed to deliver testosterone, whereas a preparation emphasizes the medicinal product available for clinical use.
Multiple branded or generic preparations may use the same general formulation type. However, identical testosterone concentrations do not necessarily establish pharmaceutical equivalence or clinical interchangeability because excipients, delivery systems, and absorption characteristics may differ [8,9].
3. Comprehensive comparison of FDA-approved testosterone formulations
| Product (pharmaceutical company) | FDA approval / NDA | Strength and administration | Advantages | Disadvantages |
|---|---|---|---|---|
| Depo-Testosterone (Pharmacia & Upjohn / Pfizer) | Historical; NDA to verify | Testosterone cypionate, 100 or 200 mg/mL; IM | Low-cost generic alternatives; flexible dose adjustment; extensive experience; no skin transfer; self-administration possible | Peaks and troughs; erythrocytosis; injection pain; needle disposal; possible symptom fluctuations; fertility suppression |
| Generic testosterone cypionate (multiple manufacturers) | Multiple ANDAs | 100 or 200 mg/mL; IM | Affordable; flexible dosing; broad availability; adjustable injection intervals | Injections; hematocrit increases; serum fluctuations; excipient-related reactions; SC use is off-label |
| Delatestryl (Endo Pharmaceuticals) | NDA 009165; historical | Testosterone enanthate, 200 mg/mL; IM | Established efficacy; flexible dosing; generic alternatives; no skin transfer | Injection discomfort; peak–trough fluctuations; erythrocytosis; needle requirements; brand availability uncertain |
| Generic testosterone enanthate (multiple manufacturers) | Multiple ANDAs | 200 mg/mL; IM | Affordable; adjustable dose; familiar pharmacokinetics | Injection frequency; fluctuations; hematocrit elevation; injection-site reactions |
| Xyosted (Antares Pharma / Halozyme Therapeutics) | 2018; NDA 209863 | Testosterone enanthate, 50, 75, or 100 mg; weekly SC autoinjector | Convenient self-administration; concealed needle; standardized dosing; relatively consistent weekly exposure; no transfer risk | Cost; fixed dose increments; injection reactions; blood pressure and hematocrit increases; device waste |
| Aveed (Endo Pharmaceuticals) | 2014; NDA 022219 | Testosterone undecanoate, 750 mg/3 mL; deep IM | Infrequent injections; sustained exposure; no daily adherence; no transfer risk | Pulmonary oil microembolism (POME); anaphylaxis; clinic observation; prolonged exposure; difficult dose adjustment; cost |
| Azmiro (Azurity Pharmaceuticals) | NDA 216318 | Testosterone cypionate, 200 mg/mL; IM | Alternative cypionate formulation; adjustable dosing; no skin transfer | Injection discomfort; hematocrit and BP increases; excipient considerations; coverage and cost variability |
| Testosterone propionate (multiple historical manufacturers) | Historical approvals; verify | Short-acting IM | Short duration; relatively rapid discontinuation; adjustable administration | Frequent injections; pain; marked fluctuations; poor convenience; limited contemporary availability |
Short-acting testosterone cypionate and enanthate are among the most flexible formulations, but infrequent administration can produce pronounced serum testosterone fluctuations [1,2].
Xyosted provides FDA-approved subcutaneous testosterone enanthate administration. Conventional injectable cypionate and enanthate products are generally labeled for intramuscular use, even though subcutaneous use occurs in clinical practice [8,10].
Aveed requires particular precautions because of POME and anaphylaxis. Its long duration also limits the ability to rapidly reduce testosterone exposure after an adverse event [8,11].
| Product (pharmaceutical company) | FDA approval / NDA | Strength and administration | Advantages | Disadvantages |
|---|---|---|---|---|
| AndroGel 1% (AbbVie / Besins Healthcare) | 2000; NDA 021015 | Testosterone gel 1%; daily | Noninvasive; adjustable dosing; relatively stable exposure; generic alternatives; no injection-related peaks | Secondary exposure; variable absorption; skin irritation; daily adherence; application restrictions |
| AndroGel 1.62% (AbbVie / Besins Healthcare) | 2011; NDA 022309 | Testosterone gel 1.62%; daily | Lower gel volume than some 1% preparations; metered dosing; no needles; extensive clinical experience | Transfer risk; absorption variability; drying and handwashing; skin reactions; daily use |
| Testim (Auxilium Pharmaceuticals / Endo Pharmaceuticals) | 2002; NDA 021454 | Testosterone gel 1%; daily | Noninvasive; established efficacy; avoids injection-related peaks | Transfer; odor or residue; skin irritation; variable absorption; daily adherence |
| Vogelxo (Upsher-Smith Laboratories) | NDA 204399 | Testosterone gel 1%; daily | Pump and unit-dose options; dose adjustment; no injections | Transfer risk; daily application; variable absorption; skin reactions |
| Fortesta (Endo Pharmaceuticals) | 2010; NDA 021463 | Testosterone gel 2%; 10 mg/actuation; thighs | Small dose increments; lower application volume; noninvasive; adjustable dosing | Transfer risk; application-site restrictions; skin irritation; daily use; current marketing status uncertain |
| Axiron (Eli Lilly and Company) | 2010; NDA 022504 | Testosterone topical solution 2%; axillae | Underarm application; noninvasive; adjustable dose; no injections | Transfer; axillary irritation; deodorant/application considerations; absorption variability; historical availability |
| Generic testosterone gel 1% (multiple manufacturers) | Multiple ANDAs | 1%; daily | Lower cost; noninvasive; different dispensing formats | Transfer; variable absorption; product-specific dosing; skin irritation |
| Generic testosterone gel 1.62% (multiple manufacturers) | Multiple ANDAs | 1.62%; daily | Generic cost advantages; metered dosing; no injections | Secondary exposure; daily adherence; absorption variability; skin reactions |
| Generic topical testosterone solution 2% (multiple manufacturers) | Multiple ANDAs | 2%; axillary application | Noninvasive; possible cost advantages; alternative application site | Transfer; irritation; drying requirements; variable absorption |
Transdermal formulations avoid the pronounced peak–trough fluctuations associated with widely spaced short-acting IM injections. However, absorption varies between patients and products [1,2].
Different gels are not necessarily interchangeable on a milligram-for-milligram basis. Application sites, dosing increments, and systemic absorption are formulation-specific [8,9].
Secondary exposure is a particularly important limitation of topical testosterone. FDA labeling includes precautions to prevent transfer to children and other individuals [8].
| Product (pharmaceutical company) | FDA approval / NDA | Strength and administration | Advantages | Disadvantages |
|---|---|---|---|---|
| Jatenzo (Tolmar Pharmaceuticals; formerly Clarus Therapeutics) | 2019; NDA 206089 | Testosterone undecanoate, 158, 198, 237 mg; twice daily with food | Oral convenience; no needles; no transfer; adjustable dosing; intestinal lymphatic absorption | Twice-daily adherence; food requirement; BP elevation; hematocrit increase; GI adverse effects; cost |
| Tlando (Verity Pharmaceuticals; formerly associated with Lipocine / Antares Pharma) | 2022; NDA 208088 | Testosterone undecanoate, 112.5 mg capsules; 225 mg twice daily with food | Fixed-dose regimen; no routine titration; no needles; no skin transfer | Limited dose flexibility; food requirement; BP elevation; hematocrit increase; twice-daily administration |
| Kyzatrex (Marius Pharmaceuticals) | 2022; NDA 213953 | Testosterone undecanoate; multiple capsule strengths; twice daily with food | Oral route; flexible titration; no skin transfer; no injections | Food-related absorption; BP elevation; hematocrit increase; GI effects; cost; twice-daily adherence |
| Methyltestosterone (multiple historical manufacturers) | Historical approvals | Oral synthetic androgen | Oral administration; historical androgen replacement use | Not testosterone itself; hepatotoxicity; cholestasis; hepatic tumors; adverse lipid effects; generally unsuitable as preferred modern TRT |
Modern oral testosterone undecanoate formulations facilitate intestinal lymphatic absorption and avoid much of the hepatic first-pass metabolism associated with conventional oral testosterone administration [2,13].
Jatenzo, Tlando, and Kyzatrex differ in dosing, titration, and pharmacokinetic monitoring. They are not interchangeable at equivalent nominal doses [8,13].
| Product (pharmaceutical company) | FDA approval / NDA | Strength and administration | Advantages | Disadvantages |
|---|---|---|---|---|
| Natesto (Acerus Pharmaceuticals; formerly Aytu BioPharma) | 2014; NDA 205488 | Intranasal testosterone gel; 11 mg three times daily | No injections; no skin transfer; short exposure; rapid cessation; potential for less sustained gonadotropin suppression in selected men | Three-times-daily dosing; nasal irritation; epistaxis; rhinorrhea; nasal disease limitations |
| Testopel (Endo Pharmaceuticals) | Historical; NDA to verify | Testosterone pellets, 75 mg; SC implantation every 3–6 months | Long duration; no daily adherence; no transfer; discreet; sustained delivery | Surgical procedure; infection; extrusion; bleeding; fibrosis; cost; difficult dose reversal |
| Androderm (Allergan / AbbVie) | Historical; NDA 020489 | Testosterone transdermal patch; daily | Continuous delivery; no injections; rapid discontinuation; no gel residue | Dermatitis; adhesive reactions; visible patch; detachment; discontinued |
| Testoderm (ALZA Corporation) | Historical; verify | Scrotal testosterone patch | Noninvasive; systemic delivery; no injections | Scrotal application; adhesion requirements; skin preparation; discontinued |
| Testoderm TTS (ALZA Corporation) | Historical; verify | Nonscrotal testosterone patch | Noninvasive; sustained delivery; no injections | Contact dermatitis; adhesive reactions; discontinued |
| Striant (Endo Pharmaceuticals; formerly Columbia Laboratories) | 2003; NDA 021543 | Buccal testosterone system, 30 mg twice daily | Avoids injections and skin transfer; bypasses GI first-pass metabolism | Gum irritation; oral discomfort; altered taste; detachment; twice-daily application; discontinued |
Intranasal testosterone has a distinctive short-duration exposure profile, whereas pellets provide sustained delivery over several months [1,2].
Transdermal patches and buccal systems are historically important but have largely been displaced by more convenient contemporary formulations.
4. Consolidated FDA regulatory inventory
The following table provides a reference for the principal brand-name testosterone preparations, associated pharmaceutical companies, FDA application identifiers, approval years, and generic availability.
| Brand | Pharmaceutical company | NDA | Initial approval | Generic availability |
|---|---|---|---|---|
| Depo-Testosterone | Pharmacia & Upjohn / Pfizer | Verify | Historical | Yes |
| Delatestryl | Endo Pharmaceuticals | 009165 | Historical | Yes |
| Xyosted | Antares Pharma / Halozyme | 209863 | 2018 | No verified equivalent autoinjector |
| Aveed | Endo Pharmaceuticals | 022219 | 2014 | No verified equivalent |
| Azmiro | Azurity Pharmaceuticals | 216318 | Verify | Generic cypionate alternatives |
| AndroGel 1% | AbbVie / Besins | 021015 | 2000 | Yes |
| AndroGel 1.62% | AbbVie / Besins | 022309 | 2011 | Yes |
| Testim | Auxilium / Endo | 021454 | 2002 | Generic alternatives |
| Vogelxo | Upsher-Smith | 204399 | Verify | Generic alternatives |
| Fortesta | Endo Pharmaceuticals | 021463 | 2010 | Generic topical alternatives |
| Axiron | Eli Lilly | 022504 | 2010 | Generic topical solution |
| Jatenzo | Tolmar Pharmaceuticals | 206089 | 2019 | No verified generic |
| Tlando | Verity Pharmaceuticals | 208088 | 2022 | No verified generic |
| Kyzatrex | Marius Pharmaceuticals | 213953 | 2022 | Authorized generic reported; verify |
| Natesto | Acerus Pharmaceuticals | 205488 | 2014 | No verified generic |
| Testopel | Endo Pharmaceuticals | Verify | Historical | Verify |
| Androderm | Allergan / AbbVie | 020489 | Historical | Discontinued |
| Testoderm | ALZA Corporation | Verify | Historical | Discontinued |
| Testoderm TTS | ALZA Corporation | Verify | Historical | Discontinued |
| Striant | Endo Pharmaceuticals | 021543 | 2003 | Discontinued |
Sources: FDA Drugs@FDA and Orange Book [8,9]. Company names include historical affiliations where applicable. Generic alternatives are not necessarily therapeutically equivalent to a specific branded delivery system.
FDA approval and current marketing status must be distinguished. Some historical preparations remain FDA-approved but are no longer marketed. Furthermore, generic products may have multiple ANDAs corresponding to different manufacturers, strengths, and presentations.
5. Comparative pharmacokinetics
Testosterone pharmacokinetics vary substantially between formulations. Administration route influences absorption, peak serum concentrations, trough concentrations, dosing frequency, and the ability to rapidly adjust treatment [1,2].
| Formulation | Administration frequency | Testosterone profile | Dosing flexibility | Rapid discontinuation |
|---|---|---|---|---|
| IM cypionate | Weekly to every 2–4 weeks | Peaks and troughs | High | Moderate |
| IM enanthate | Weekly to every 2–4 weeks | Peaks and troughs | High | Moderate |
| SC enanthate autoinjector | Weekly | Relatively consistent weekly exposure | Moderate | Moderate |
| IM undecanoate | Approximately every 10 weeks after loading | Prolonged exposure | Low | Poor |
| Transdermal gel | Daily | Relatively stable daily exposure | Moderate–high | Good |
| Oral undecanoate | Twice daily | Absorption-related peaks | Product-dependent | Good |
| Intranasal gel | Three times daily | Short peaks | Limited | Excellent |
| Pellets | Every 3–6 months | Sustained release and gradual decline | Low | Poor |
| Transdermal patch | Daily | Continuous delivery | Moderate | Good |
| Buccal system | Twice daily | Repeated sustained exposure | Limited | Good |
These patterns are generalizations. Individual pharmacokinetic responses can differ substantially, and serum testosterone monitoring must follow product-specific instructions.
6. Comparative safety and tolerability
6.1 Erythrocytosis
Testosterone stimulates erythropoiesis and can increase hemoglobin and hematocrit.
In a systematic review and Bayesian network meta-analysis of randomized trials, Nackeeran et al. found that all evaluated testosterone formulations significantly increased hematocrit relative to placebo [3].
The analysis suggested a greater hematocrit increase with short-acting intramuscular testosterone enanthate/cypionate than with transdermal patches, but statistically significant differences were not demonstrated for most other formulation comparisons [3].
An observational study by Pastuszak et al. reported erythrocytosis, defined as hematocrit greater than 50%, in 66.7% of injection users, 35.1% of pellet users, and 12.8% of gel users [14]. These findings are clinically relevant but cannot establish causal differences because the treatment groups were not randomized.
Hematocrit monitoring is required regardless of formulation.
6.2 Cardiovascular safety
The TRAVERSE trial randomized 5,246 men with hypogonadism and preexisting or elevated cardiovascular risk to testosterone gel 1.62% or placebo [4].
Testosterone gel
7.0%
Major adverse cardiovascular events
Placebo
7.3%
Major adverse cardiovascular events
The primary cardiovascular endpoint met the prespecified noninferiority criterion [4].
However, these results cannot be assumed to apply equally to every testosterone formulation. Blood pressure increases remain clinically important, and FDA labeling includes blood pressure warnings [5,6].
6.3 Fertility
Exogenous testosterone suppresses the hypothalamic–pituitary–gonadal axis and may substantially reduce sperm production.
This effect is not restricted to a particular administration route. Men actively attempting conception should generally avoid exogenous testosterone and discuss fertility-preserving alternatives with a specialist [1,2].
Some studies suggest intranasal testosterone may cause less sustained gonadotropin suppression in selected patients. Nevertheless, Natesto is not FDA-approved for fertility preservation.
6.4 Route-specific adverse effects
| Formulation | Principal concerns |
|---|---|
| IM cypionate/enanthate | Injection pain, serum fluctuations, erythrocytosis |
| SC enanthate | Injection reactions, hematocrit and BP increases |
| IM undecanoate | POME, anaphylaxis, prolonged exposure |
| Transdermal gels | Secondary transfer, skin reactions, absorption variability |
| Oral undecanoate | BP increases, GI effects, hematocrit elevation |
| Intranasal gel | Nasal irritation, epistaxis, frequent dosing |
| Pellets | Infection, extrusion, bleeding, fibrosis |
| Patches | Contact dermatitis, adhesive reactions |
| Buccal systems | Gingival irritation, oral discomfort |
7. Clinical selection of testosterone formulations
No single testosterone formulation is optimal for every patient.
| Clinical priority | Potentially suitable formulations | Important limitations |
|---|---|---|
| Lowest treatment cost | Generic testosterone cypionate/enanthate | Injection requirements; serum fluctuations |
| Avoid injections | Transdermal gels, oral TU, Natesto | Transfer, dosing frequency, absorption issues |
| Avoid skin transfer | Injections, oral TU, Natesto, pellets | Other adverse effects remain |
| Infrequent administration | Aveed, Testopel | Limited reversibility |
| Flexible dosing | Conventional injections, selected gels | Requires monitoring and titration |
| Avoid large injection peaks | Daily gels, weekly SC enanthate | Individual exposure varies |
| Rapid cessation | Intranasal gel, daily topical preparations | Systemic effects may persist after discontinuation |
| Concern about erythrocytosis | Consider alternatives to large intermittent IM doses | No route eliminates risk |
| Avoid daily administration | Weekly injections, Aveed, pellets | Injection or procedural requirements |
Clinical decisions should consider hematocrit, cardiovascular risk, blood pressure, fertility goals, cost, insurance coverage, patient preferences, and treatment response [1–3].
8. Testosterone formulations in women
No systemic testosterone product is FDA-approved specifically for treating HSDD or other symptoms in women [7].
The ISSWSH guideline supports systemic transdermal testosterone therapy for appropriately selected women with HSDD, with dosing intended to maintain serum concentrations within the physiological premenopausal female range [15].
When female-specific approved products are unavailable, clinicians may prescribe carefully adjusted doses of male-approved transdermal preparations off-label.
However, male formulations were not designed for female dosing, and careful monitoring is required to avoid supraphysiological testosterone exposure.
Injectable formulations and pellets are generally discouraged for HSDD treatment in women because of the potential for supraphysiological concentrations and difficulty with dose adjustment [15].
9. Conclusions
FDA-approved testosterone preparations differ substantially in their pharmacokinetics, administration requirements, cost, dose flexibility, and adverse-effect profiles.
Generic short-acting injectable esters offer affordability and flexible dosing but can produce considerable serum testosterone fluctuations. Transdermal gels permit noninvasive administration and relatively rapid dose adjustment, although secondary exposure and variable absorption remain important limitations.
Modern oral testosterone undecanoate formulations eliminate injections and skin-transfer concerns but require twice-daily administration and blood pressure monitoring. Long-acting injections and pellets reduce administration frequency while limiting rapid dose modification or discontinuation.
Comparative studies suggest differences in erythrocytosis risk, but evidence remains insufficient to establish one formulation as universally superior for long-term cardiovascular or other clinical outcomes [3,4,14].
The optimal formulation should therefore be individualized according to clinical characteristics, patient preferences, safety considerations, and treatment response.
References
Numbered in order of first citation. Sources are restricted to FDA publications and PubMed-indexed scientific literature.
1. Shoskes JJ, Wilson MK, Spinner ML. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834–843. PMID
2. U.S. Food and Drug Administration. FDA regulatory review of testosterone preparations. 2023.
3. Nackeeran S, Kohn T, Gonzalez D, et al. The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network meta-analysis of randomized trials. J Urol. 2022;207(1):44–51. PMID
4. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–117. PMID
5. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025.
6. U.S. Food and Drug Administration. Testosterone information. Updated 2026.
7. U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee: Testosterone briefing document. October 29, 2024.
8. U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs.
9. U.S. Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).
10. U.S. Food and Drug Administration. Xyosted (testosterone enanthate) injection: FDA-approved prescribing information. NDA 209863.
11. U.S. Food and Drug Administration. Testosterone undecanoate and other testosterone products: risk evaluation and mitigation strategy review. 2023.
12. U.S. Food and Drug Administration. FDA-approved testosterone replacement therapies: regulatory inventory. 2015.
13. U.S. Food and Drug Administration. Jatenzo (testosterone undecanoate) capsules: prescribing information. NDA 206089. 2025.
14. Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. Sex Med. 2015;3(3):165–173. PMID
15. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849–867. PMID